Abstract
Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in developed countries.1 Patients with nonalcoholic steatohepatitis (NASH) are considered to be at a higher risk of fibrosis progression and development to cirrhosis and hepatocellular carcinoma.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Carcinoma, Hepatocellular* / pathology
-
Disease Progression
-
Glycine / analogs & derivatives
-
Glyphosate
-
Humans
-
Liver / pathology
-
Liver Cirrhosis / pathology
-
Liver Neoplasms* / pathology
-
Non-alcoholic Fatty Liver Disease* / complications
-
Non-alcoholic Fatty Liver Disease* / pathology